Intellectual Product
AstraZeneca Ordered to Pay Pfizer Over $107 Million in Tagrisso Patent Infringement Case
AstraZeneca, Pfizer, Tagrisso, patent infringement, jury verdict, damages, lung cancer treatment
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.
Ascendis Hormone Replacement Therapy Faces Setback with FDA Review Extension
Ascendis Pharma, hormone replacement therapy, FDA review, delay, three-month extension.
FDA Rejects Hepatitis B Vaccine Update Due to Inadequate Documentation and Data
FDA, hepatitis B vaccine, vaccine update, document destruction, insufficient data, rejection
Extended FDA Review Timeline for Ascendis’ Hormone Therapy
Ascendis Pharma, hormone therapy, FDA review, delay, 3 months extension.
Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS
Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.
Cytokinetics Unveils Aficamten Data, Gears Up for Market Competition Against Camzyos
Cytokinetics, Aficamten, Camzyos, clinical data, cardiovascular disease, myotonic dystrophy, heart failure, commercial strategy, market competition.
Takeda Pharmaceuticals Revises Profit Forecast Due to Vyvanse Patent Expiration, Plans $900M Restructuring by 2024
Takeda Pharmaceuticals, Vyvanse, patent expiration, profit outlook, restructuring, ADHD medication
Intellectual property landscape around prime editing
Intellectual Property Landscape Around Prime Editing Prime editing, a revolutionary genome editing technology, has been at the forefront of significant intellectual property developments and patent disputes. This technology, which allows for precise DNA edits without the need for double-strand breaks, was developed by Dr. David Liu and his team at the Broad Institute and Harvard […]
Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer
Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.